Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Interplay between chronic inflammation and clonal haematopoiesis of indeterminate potential in Behçet’s disease
Beteiligte:
Park, Jihye;
An, Hongyul;
Lim, Jiwoo;
Park, I Seul;
Kim, Mi Hyun;
Kim, Ji Hyung;
Kim, Seung Won;
Koh, Young Il;
Lee, Eun Young;
Cheon, Jae Hee
Erschienen:
Springer Science and Business Media LLC, 2023
Erschienen in:Arthritis Research & Therapy
Sprache:
Englisch
DOI:
10.1186/s13075-023-03014-w
ISSN:
1478-6362
Entstehung:
Anmerkungen:
Beschreibung:
<jats:title>Abstract</jats:title><jats:sec>
<jats:title>Background</jats:title>
<jats:p>Clonal haematopoiesis of indeterminate potential (CHIP) is a predisposition to haematological malignancy whose relationship with chronic inflammatory diseases, such as cardiovascular diseases, has been highlighted. Here, we aimed to investigate the CHIP emergence rate and its association with inflammatory markers in Behçet’s disease (BD).</jats:p>
</jats:sec><jats:sec>
<jats:title>Methods</jats:title>
<jats:p>We performed targeted next-generation sequencing to detect the presence of CHIP using peripheral blood cells from 117 BD patients and 5004 healthy controls between March 2009 and September 2021 and analysed the association between CHIP and inflammatory markers.</jats:p>
</jats:sec><jats:sec>
<jats:title>Results</jats:title>
<jats:p>CHIP was detected in 13.9% of patients in the control group and 11.1% of patients in the BD group, indicating no significant intergroup difference. Among the BD patients of our cohort, five variants (<jats:italic>DNMT3A</jats:italic>, <jats:italic>TET2</jats:italic>, <jats:italic>ASXL1</jats:italic>, <jats:italic>STAG2</jats:italic>, and <jats:italic>IDH2</jats:italic>) were detected. <jats:italic>DNMT3A</jats:italic> mutations were the most common, followed by <jats:italic>TET2</jats:italic> mutations. CHIP carriers with BD had a higher serum platelet count, erythrocyte sedimentation rate, and C-reactive protein level; older age; and lower serum albumin level at diagnosis than non-CHIP carriers with BD. However, the significant association between inflammatory markers and CHIP disappeared after the adjustment for various variables, including age. Moreover, CHIP was not an independent risk factor for poor clinical outcomes in patients with BD.</jats:p>
</jats:sec><jats:sec>
<jats:title>Conclusions</jats:title>
<jats:p>Although BD patients did not have higher CHIP emergence rates than the general population, older age and degree of inflammation in BD were associated with CHIP emergence.</jats:p>
</jats:sec>